Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Stocks in news: IFCI, Tata Motors, General Insurance Corp, Corona Remedies, HFCL
Markets extended their winning streak for the fourth consecutive session, driven by favorable global cues and sustained sector-wide buying. The Nifty reclaimed the 24,000 mark, approaching the 100-day EMA near 24,150. Stocks like IFCI, Tata Motors, and HFCL are in focus due to significant news developments, including IPO filings, turnaround projections, and major order wins.
HDFC MF, ADIA among buyers as Sepia Investments offloads Rs 749 crore in Corona Remedies via block deal
Sepia Investments and Anchor Partners sold shares worth about Rs 777 crore in Corona Remedies through block deals. HDFC Mutual Fund emerged as the largest buyer, while several institutional investors, including Aberdeen entities, ADIA, Invesco and WhiteOak, also accumulated stakes.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
SBI in $1 billion funding for Sun Pharma’s US deal
State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.

Small-caps, PSUs and pharma remain Gautam Shah's top market themes for 2026
Gautam Shah, Founder of Goldilocks Global Research, sees the Nifty remaining range-bound between 23,150 and 24,000, while forecasting the small-cap index could rise to 20,000. Shah also believes Indian IT stocks are nearing a bottom and that PSU stocks could deliver 25-30% returns over the next 12-18 months.
Sensex falls 70 points, Nifty below 23,900 as US-Iran tensions simmer
Indian stock markets opened lower on Wednesday. Sensex and Nifty saw minor declines. Investors are watching US strikes on Iran and their effect on peace deal hopes. Broader markets are performing better. India VIX, a volatility measure, dropped. Top Sensex losers included HDFC Bank and Infosys. Sun Pharma shares led gains. Midcap and smallcap indices saw small gains.

Top Gainers & Losers on May 18: Gland Pharma, Coforge, PB Fintech, BSE, Voltas, Bharti Airtel among top gainers
Indian stocks marginally gained on May 18, driven by strong tech buying and pharma support, with Nifty 50 up 0.03% at 23,649 and BSE Sensex at 75,263. However, the broader market faced pressure as Nifty Midcap 100 and Nifty Smallcap 100 fell.

Market at Close | Bharti Airtel, Cipla lead rally as Sensex jumps 790 points, Nifty tops 23,650
The Sensex rose 790 points to close at 75,399, while the Nifty gained 277 points to settle at 23,690. The Nifty Bank index advanced 673 points to 54,129, and the Midcap index climbed 675 points to 60,840.
Vodafone Idea and 4 other midcap stocks hit 52-week highs, rally up to 40% in a month
Benchmark indices ended marginally higher as five BSE 150 Midcap stocks touched fresh 52-week highs, reflecting strong investor sentiment and bullish momentum. Vodafone Idea, SAIL, MCX, Laurus Labs and Ajanta Pharma recorded notable monthly gains, signalling sustained buying interest despite subdued broader market performance overall.